Overview
Desmopressin (DDAVP) is a synthetic analogue of the endogenous posterior pituitary hormone arginine vasopressin (AVP), modified at two positions: deamination of the N-terminal cysteine (1-desamino) and substitution of L-arginine with D-arginine at position 8. These changes increase antidiuretic potency 8–10 fold, extend half-life 2–4 fold, and virtually eliminate vasopressor activity. FDA-approved since 1978 across multiple formulations, Desmopressin is the standard of care for central diabetes insipidus, nocturnal enuresis, hemophilia A, and von Willebrand disease type 1.
Mechanism of action
Desmopressin acts as a selective V2 vasopressin receptor agonist with minimal V1 receptor activity. V2 receptor activation in renal collecting duct principal cells triggers Gs-coupled adenylyl cyclase activation, elevating intracellular cyclic AMP. cAMP activates protein kinase A, which phosphorylates aquaporin-2 (AQP2) water channels, driving their translocation from cytoplasmic vesicles to the apical membrane. The resulting increase in apical membrane water permeability allows passive water reabsorption from urine into the hyperosmotic medullary interstitium, concentrating urine and reducing urine volume. In hemostasis, V2 receptor activation in vascular endothelial cells triggers release of stored von Willebrand factor (vWF) from Weibel-Palade bodies and increases plasma factor VIII levels through stabilization by vWF, correcting the coagulation defect in mild hemophilia A and type 1 von Willebrand disease.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| central diabetes insipidus (oral) | oral | 0.05–0.4 mg | two to three times daily | Start 0.05 mg twice daily, titrate based on urine output and osmolality. Total daily dose typically 0.1–0.8 mg in divided doses. |
| nocturnal enuresis (nasal) | nasal | 10–40 mcg | once nightly | Standard dose 20 mcg intranasally at bedtime. Restrict fluid intake 1 hour before through 8 hours after dosing to prevent hyponatremia. |
| hemophilia A / von Willebrand disease (IV/SC) | subcutaneous | 0.3–0.3 mcg/kg | single dose pre-procedure | 0.3 mcg/kg IV infused over 15–30 minutes or SC. Repeat dosing risks tachyphylaxis due to vWF store depletion. Maximum response after 30–90 minutes. |
| hemophilia A / von Willebrand disease (IV) | intravenous | 0.3–0.3 mcg/kg | single dose pre-procedure | Infuse over 15–30 minutes. Monitor blood pressure during infusion. Repeat doses may have diminished effect. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Desmopressin has extensive clinical evidence across decades of use. Randomized controlled trials in nocturnal enuresis demonstrate 60–70% reduction in bedwetting nights versus placebo. Central diabetes insipidus management trials confirm near-complete restoration of normal urine output and osmolality. In hemophilia A, desmopressin produces 3–5-fold increases in plasma factor VIII suitable for minor surgical prophylaxis in mild-moderate disease. A 2022 FDA-approved low-dose sublingual tablet (Nocdurna) extended the indication to nocturia due to nocturnal polyuria in adults. Long-term use carries risk of hyponatremia, particularly in children and elderly patients, requiring careful fluid restriction.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Legal status
FDA-approved since February 1978. Available as intranasal spray (DDAVP Nasal Spray), oral tablets (DDAVP Tablets), sublingual tablets (Nocdurna), and IV/SC injection (DDAVP Injection). Multiple generic formulations available. Prescription required in the US and most jurisdictions. Some OTC availability in certain countries for bedwetting formulations.
Where to get it
Prescription required
Desmopressin is a prescription medication. Consult your healthcare provider or a licensed telehealth platform for access.